Industry Overview of Antisense & RNAi Therapeutics Market
Antisense therapy represents the selective and sequence-specific inhibition of gene expression by single-stranded DNA oligonucleotides. It regulates cell function and division and can modulate cellular responses to internal and external stresses and stimuli. Antisense therapy is also used for treating amyotrophic lateral sclerosis and Huntington's and Alzheimer's disease. On the other hand, RNA interference (RNAi) therapy is triggered by double-stranded RNA (dsRNA) and causes sequence-specific ribonucleic acid (mRNA) degradation of single-stranded target RNAs in response to dsRNA. It is utilized for treating numerous respiratory disorders, including asthma and chronic obstructive pulmonary disease (COPD). RNAi therapy also helps in preventing the production of specific genes that cause diseases.
How Big Is the Antisense & RNAi Therapeutics Market?
The global antisense & RNAi therapeutics market size reached US$ 1.5 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.5 Billion by 2028, exhibiting a growth rate (CAGR) of 8.3% during 2023-2028.
Global Industry Trends and Drivers:
The escalating demand for these therapies to treat uncommon neurodegenerative diseases, such as hereditary ATTR amyloidosis, is primarily driving the antisense and RNAi therapeutics market. Furthermore, the elevating requirement for disease management to regulate gene expression by malfunctioning genes across several countries is also augmenting the market growth. Apart from this, the expanding healthcare industry is positively influencing the global market. Moreover, key market players are extensively investing in research and development (R&D) activities to develop molecules based on antisense technology, which is further bolstering the market growth. Besides this, the rising need for antisense RNA to prevent disease onset and reduce disorder progression is acting as another significant growth-inducing factor. Additionally, the increasing demand for curing and preventing diseases, including cancer, human immunodeficiency virus (HIV), and other disorders caused by mutating viruses, is expected to drive the antisense and RNAi therapeutics market in the coming years.
What Is Included In Market Segmentation?
The report has been segmented the market into following categories:
Breakup by Technology:
- RNA Interference
- siRNA
- miRNA
- Antisense RNA
Breakup by Route of Administration:
- Intravenous Route
- Subcutaneous Route
- Intrathecal Route
- Pulmonary Delivery
- Intraperitoneal Injection
- Others
Breakup by Application:
- Oncology
- Cardiovascular Diseases (CVDs)
- Respiratory Disorders
- Renal Diseases
- Neurodegenerative Disorders
- Genetic Disorders
- Infectious Diseases
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report provides a comprehensive analysis of the industry key players listed below:
Alnylam Pharmaceuticals Inc., Arbutus Biopharma Corporation, Arrowhead Pharmaceuticals Inc., Benitec Biopharma Ltd., Bio-Path Holdings Inc., Dicerna Pharmaceuticals Inc. (Novo Nordisk A/S), Ionis Pharmaceuticals Inc., OliX Pharmaceuticals Inc., Phio Pharmaceuticals Corp., Sarepta Therapeutics Inc., Silence Therapeutics and Sirnaomics Inc.
